Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation
Authors:
- 15 May 2018
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 58 (10) , 1266-1273
Abstract
The aim of this pharmacokinetic/pharmacodynamic (PK/PD) study is to evaluate the efficacy of various isavuconazole dosing regimens for healthy individuals and patients with hepatic or renal impairment against Aspergillusspp. and Candidaspp. Monte Carlo simulations were conducted using pharmacokinetic (PK) parameters and pharmacodynamics (PD) data to determine the probabilities of target attainment and cumulative fractions of response in terms of area under the concentration curve/minimum inhibition concentration (AUC/MIC) targets of isavuconazole. A clinically recommended dosage regimen of isavuconazole (200mgqd) obtained high cumulative fraction of response values of>90% for all subjects against A. fumigatus, A. flavus, A. nidulans, A. terreus, A. versicolor, C. parapsilosis and C. tropicalis. For patients with mild or moderate hepatic impairment, the dosage should be halved only when treating invasive fungal infections caused by C. albicans, C. parapsilosis or C. tropicalis. However, dose adjustment is unlikely to be required in mild to severe renal impairment patients because all cumulative fraction of response values were similar to those of comparing with healthy subjects. Notably, all isavuconazole dosing regimens were not effective against C. glabrata and C. krusei in all subjects. These PK/PD-based simulations rationalize and optimize the dosage regimens of isavuconazole for healthy individuals and patients with hepatic or renal impairment against Aspergillusspp. and Candidaspp.Keywords
Funding Information
- Zhejiang Provincial Program for the Cultivation of High-level Innovative Heath Talents
- Zhejiang Provincial Program for 151 Talents
This publication has 20 references indexed in Scilit:
- IsavuconazoleAnnals of Pharmacotherapy, 2015
- Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection ModelAntimicrobial Agents and Chemotherapy, 2015
- Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation StudyAntimicrobial Agents and Chemotherapy, 2015
- Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseasesExpert Review of Anti-infective Therapy, 2014
- Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2013
- Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2013
- Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infectionsExpert Opinion on Drug Metabolism & Toxicology, 2012
- New generation azole antifungals in clinical investigationExpert Opinion on Investigational Drugs, 2009
- Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in EuropeJournal of Antimicrobial Chemotherapy, 2005